Pharmacological Validation of Trypanosoma brucei Phosphodiesterases B1 and B2 as Druggable Targets for African Sleeping Sickness

作者：Bland Nicholas D; Wang Cuihua; Tallman Craig; Gustafson Alden E; Wang Zhouxi; Ashton Trent D; Ochiana Stefan O; McAllister Gregory; Cotter Kristina; Fang Anna P; Gechijian Lara; Garceau Norman; Gangurde Rajiv; Ortenberg Ron; Ondrechen Mary Jo; Campbell Robert K; Pollastri Michael P^*

来源：Journal of Medicinal Chemistry, 2011, 54(23): 8188-8194.

DOI：10.1021/jm201148s

Neglected tropical disease drug discovery requires application of pragmatic and efficient methods for development of new therapeutic agents. In this report, we describe our target repurposing efforts for the essential phosphodiesterase (PDE) enzymes TbrPDEB1 and TbrPDEB2 of Trypanosoma brucei, the causative agent for human African trypanosomiasis (HAT). We describe protein expression and purification, assay development, and benchmark screening of a collection of 20 established human PDE inhibitors. We disclose that the human PDE4 inhibitor piclamilast, and some of its analogues, show modest inhibition of TbrPDEB1 and B2 and quickly kill the bloodstream form of the subspecies T. brucei brucei. We also report the development of a homology model of TbrPDEB1 that is useful for understanding the compound-enzyme interactions and for comparing the parasitic and human enzymes. Our profiling and early medicinal chemistry results strongly suggest that human PDE4 chemotypes represent a better starting point for optimization of TbrPDEB inhibitors than those that target any other human PDEs.

• 出版日期2011-12-8
• 单位东北大学